胃食道逆流症(GERD)的全球市场 2023-2027年

GERD的市场规模在2022年～2027年间，预测将成长到9亿849万美元，在预测期间内预计将以年复合成长率3.4％增长。

本报告提供GERD市场整体分析，提供市场规模与预测，趋势，网罗了成长促进因素·课题，再加上约25家供应商的供应商分析等资讯。

同时本报告还提供当前全球市场趋势与推动因素以及整体市场环境的最新分析。市场成长的主要因素有老年人口的增加，生活习惯的恶化，医药品和营养补充品的过剩使用。

目录

第1章 摘要整理

• 市场概要

第2章 市场形势

• 市场生态系统

第3章 市场规模

• 市场定义
• 市场区隔分析
• 市场规模 2022
• 市场预测:2022-2027年的预测

第4章 市场规模实际成果

• 世界GERD市场2017～2021年
• 给药途径市场区隔分析2017-2021
• 药物类型市场区隔分析2017-2021
• 地区市场区隔分析2017-2021
• 国家市场区隔分析2017-2021

第5章 波特的五力分析

• 五力的摘要
• 买方议价能力
• 供给企业谈判力
• 新加入厂商业者的威胁
• 替代品的威胁
• 竞争的威胁
• 市场情况

第6章 管理各途径市场区隔

• 市场·市场区隔
• 各给药途径比较
• 口服 - 市场规模与预测 2022-2027
• 非口服 - 市场规模与预测 2022-2027
• 各给药途径的市场机会

第7章 各类型的市场区隔

• 市场·市场区隔
• 各类型比较
• 制酸剂 - 市场规模与预测 2022-2027
• PPI - 市场规模与预测 2022-2027
• H2受体拮抗剂 - 市场规模与预测 2022-2027
• 运动促进药 - 市场规模与预测 2022-2027
• 各类型的市场机会

第8章 客户形势

• 客户形势概要

第9章 各地区形势

• 各地区市场区隔
• 各地区比较
• 北美 - 市场规模与预测 2022-2027
• 欧洲 - 市场规模与预测 2022-2027
• 亚洲 - 市场规模与预测 2022-2027
• 其他地区(ROW) - 市场规模与预测 2022-2027
• 美国 - 市场规模与预测 2022-2027
• 德国 - 市场规模与预测 2022-2027
• 英国 - 市场规模与预测 2022-2027
• 中国 - 市场规模与预测 2022-2027
• 加拿大 - 市场规模与预测 2022-2027
• 各地区的市场机会

第10章 促进因素，课题，及的趋势

• 推动市场要素
• 市场课题
• 推动因素与课题的影响
• 市场趋势

第11章 业者情势

• 概要
• 业者情势
• 混乱状况
• 产业的风险

第12章 供应商分析

• 交易厂商
• 供应商的市场定位
• Abbott Laboratories
• Alkem Laboratories Ltd.
• Apotex Inc.
• AstraZeneca Plc
• Aurobindo Pharma Ltd.
• Bayer AG
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eisai Co. Ltd.
• Fresenius SE and Co. KGaA
• GlaxoSmithKline Plc
• iNova Pharmaceuticals
• Johnson and Johnson
• Lupin Ltd.
• Perrigo Co. Plc

第13章 附录

Technavio has been monitoring the GERD market and is forecast to grow by $908.49 mn during 2022-2027, accelerating at a CAGR of 3.4% during the forecast period. Our report on the GERD market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising geriatric population, poor lifestyle patterns, and overuse of medicines and dietary supplements.

Technavio's GERD market is segmented as below:

By Route of Administration

• Oral
• Parenteral

By Type

• Antacid
• PPI
• H2 receptor antagonist drugs
• Pro-Kinetic drugs

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising prevalence of obesity as one of the prime reasons driving the GERD market growth during the next few years. Also, the growing e-commerce market and increasing awareness of GERD will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the GERD market covers the following areas:

• GERD market sizing
• GERD market forecast
• GERD market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position. In line with this, this report provides a detailed analysis of several leading GERD market vendors that include Bayer AG, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, iNova Pharmaceuticals, Johnson and Johnson, Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., The Procter and Gamble Co., and Abbott Laboratories. Also, the GERD market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market by Geography
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global GERD market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global GERD market 2017 - 2021 ($ million)
• 4.2 Route of Administration Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
• 4.3 Drug Type Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Drug Type Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
• 6.2 Comparison by Route of Administration
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration
• 6.3 Oral - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
• 6.4 Parenteral - Market size and forecast 2022-2027
• Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
• 6.5 Market opportunity by Route of Administration
• Exhibit 42: Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 43: Chart on Type - Market share 2022-2027 (%)
• Exhibit 44: Data Table on Type - Market share 2022-2027 (%)
• 7.2 Comparison by Type
• Exhibit 45: Chart on Comparison by Type
• Exhibit 46: Data Table on Comparison by Type
• 7.3 Antacid - Market size and forecast 2022-2027
• Exhibit 47: Chart on Antacid - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on Antacid - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on Antacid - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Antacid - Year-over-year growth 2022-2027 (%)
• 7.4 PPI - Market size and forecast 2022-2027
• Exhibit 51: Chart on PPI - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on PPI - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on PPI - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on PPI - Year-over-year growth 2022-2027 (%)
• 7.5 H2 receptor antagonist drugs - Market size and forecast 2022-2027
• Exhibit 55: Chart on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
• 7.6 Pro-Kinetic drugs - Market size and forecast 2022-2027
• Exhibit 59: Chart on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
• 7.7 Market opportunity by Type
• Exhibit 63: Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 65: Chart on Market share by geography 2022-2027 (%)
• Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 67: Chart on Geographic comparison
• Exhibit 68: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.10 China - Market size and forecast 2022-2027
• Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity by geography
• Exhibit 105: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 106: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 108: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 109: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 110: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 111: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 112: Abbott Laboratories - Overview
• Exhibit 113: Abbott Laboratories - Business segments
• Exhibit 114: Abbott Laboratories - Key news
• Exhibit 115: Abbott Laboratories - Key offerings
• Exhibit 116: Abbott Laboratories - Segment focus
• 12.4 Alkem Laboratories Ltd.
• Exhibit 117: Alkem Laboratories Ltd. - Overview
• Exhibit 118: Alkem Laboratories Ltd. - Business segments
• Exhibit 119: Alkem Laboratories Ltd. - Key news
• Exhibit 120: Alkem Laboratories Ltd. - Key offerings
• Exhibit 121: Alkem Laboratories Ltd. - Segment focus
• 12.5 Apotex Inc.
• Exhibit 122: Apotex Inc. - Overview
• Exhibit 123: Apotex Inc. - Product / Service
• Exhibit 124: Apotex Inc. - Key offerings
• 12.6 AstraZeneca Plc
• Exhibit 125: AstraZeneca Plc - Overview
• Exhibit 126: AstraZeneca Plc - Product / Service
• Exhibit 127: AstraZeneca Plc - Key news
• Exhibit 128: AstraZeneca Plc - Key offerings
• 12.7 Aurobindo Pharma Ltd.
• Exhibit 129: Aurobindo Pharma Ltd. - Overview
• Exhibit 130: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 131: Aurobindo Pharma Ltd. - Key offerings
• 12.8 Bayer AG
• Exhibit 132: Bayer AG - Overview
• Exhibit 133: Bayer AG - Business segments
• Exhibit 134: Bayer AG - Key news
• Exhibit 135: Bayer AG - Key offerings
• Exhibit 136: Bayer AG - Segment focus
• 12.9 Cipla Ltd.
• Exhibit 137: Cipla Ltd. - Overview
• Exhibit 138: Cipla Ltd. - Business segments
• Exhibit 139: Cipla Ltd. - Key news
• Exhibit 140: Cipla Ltd. - Key offerings
• Exhibit 141: Cipla Ltd. - Segment focus
• 12.10 Dr Reddys Laboratories Ltd.
• Exhibit 142: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 143: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 144: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 145: Dr Reddys Laboratories Ltd. - Segment focus
• 12.11 Eisai Co. Ltd.
• Exhibit 146: Eisai Co. Ltd. - Overview
• Exhibit 147: Eisai Co. Ltd. - Business segments
• Exhibit 148: Eisai Co. Ltd. - Key offerings
• Exhibit 149: Eisai Co. Ltd. - Segment focus
• 12.12 Fresenius SE and Co. KGaA
• Exhibit 150: Fresenius SE and Co. KGaA - Overview
• Exhibit 151: Fresenius SE and Co. KGaA - Business segments
• Exhibit 152: Fresenius SE and Co. KGaA - Key news
• Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
• Exhibit 154: Fresenius SE and Co. KGaA - Segment focus
• 12.13 GlaxoSmithKline Plc
• Exhibit 155: GlaxoSmithKline Plc - Overview
• Exhibit 156: GlaxoSmithKline Plc - Business segments
• Exhibit 157: GlaxoSmithKline Plc - Key offerings
• Exhibit 158: GlaxoSmithKline Plc - Segment focus
• 12.14 iNova Pharmaceuticals
• Exhibit 159: iNova Pharmaceuticals - Overview
• Exhibit 160: iNova Pharmaceuticals - Product / Service
• Exhibit 161: iNova Pharmaceuticals - Key offerings
• 12.15 Johnson and Johnson
• Exhibit 162: Johnson and Johnson - Overview
• Exhibit 163: Johnson and Johnson - Business segments
• Exhibit 164: Johnson and Johnson - Key news
• Exhibit 165: Johnson and Johnson - Key offerings
• Exhibit 166: Johnson and Johnson - Segment focus
• 12.16 Lupin Ltd.
• Exhibit 167: Lupin Ltd. - Overview
• Exhibit 168: Lupin Ltd. - Product / Service
• Exhibit 169: Lupin Ltd. - Key news
• Exhibit 170: Lupin Ltd. - Key offerings
• 12.17 Perrigo Co. Plc
• Exhibit 171: Perrigo Co. Plc - Overview
• Exhibit 172: Perrigo Co. Plc - Business segments
• Exhibit 173: Perrigo Co. Plc - Key news
• Exhibit 174: Perrigo Co. Plc - Key offerings
• Exhibit 175: Perrigo Co. Plc - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 176: Inclusions checklist
• Exhibit 177: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 178: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 179: Research methodology
• Exhibit 180: Validation techniques employed for market sizing
• Exhibit 181: Information sources
• 13.5 List of abbreviations
• Exhibit 182: List of abbreviations

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market by Geography
• Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits6: Executive Summary - Chart on Market Segmentation by Type
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global GERD market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Drug Type Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Route of Administration
• Exhibits33: Data Table on Comparison by Route of Administration
• Exhibits34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
• Exhibits42: Market opportunity by Route of Administration ($ million)
• Exhibits43: Chart on Type - Market share 2022-2027 (%)
• Exhibits44: Data Table on Type - Market share 2022-2027 (%)
• Exhibits45: Chart on Comparison by Type
• Exhibits46: Data Table on Comparison by Type
• Exhibits47: Chart on Antacid - Market size and forecast 2022-2027 ($ million)
• Exhibits48: Data Table on Antacid - Market size and forecast 2022-2027 ($ million)
• Exhibits49: Chart on Antacid - Year-over-year growth 2022-2027 (%)
• Exhibits50: Data Table on Antacid - Year-over-year growth 2022-2027 (%)
• Exhibits51: Chart on PPI - Market size and forecast 2022-2027 ($ million)
• Exhibits52: Data Table on PPI - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Chart on PPI - Year-over-year growth 2022-2027 (%)
• Exhibits54: Data Table on PPI - Year-over-year growth 2022-2027 (%)
• Exhibits55: Chart on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits56: Data Table on H2 receptor antagonist drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Chart on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
• Exhibits58: Data Table on H2 receptor antagonist drugs - Year-over-year growth 2022-2027 (%)
• Exhibits59: Chart on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits60: Data Table on Pro-Kinetic drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits61: Chart on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
• Exhibits62: Data Table on Pro-Kinetic drugs - Year-over-year growth 2022-2027 (%)
• Exhibits63: Market opportunity by Type ($ million)
• Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits65: Chart on Market share by geography 2022-2027 (%)
• Exhibits66: Data Table on Market share by geography 2022-2027 (%)
• Exhibits67: Chart on Geographic comparison
• Exhibits68: Data Table on Geographic comparison
• Exhibits69: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits71: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits72: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits75: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits79: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits85: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits86: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits87: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits88: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits89: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits90: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits91: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits92: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits97: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits98: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits99: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits100: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits103: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits105: Market opportunity by geography ($ million)
• Exhibits106: Impact of drivers and challenges in 2022 and 2027
• Exhibits107: Overview on Criticality of inputs and Factors of differentiation
• Exhibits108: Overview on factors of disruption
• Exhibits109: Impact of key risks on business
• Exhibits110: Vendors covered
• Exhibits111: Matrix on vendor position and classification
• Exhibits112: Abbott Laboratories - Overview
• Exhibits113: Abbott Laboratories - Business segments
• Exhibits114: Abbott Laboratories - Key news
• Exhibits115: Abbott Laboratories - Key offerings
• Exhibits116: Abbott Laboratories - Segment focus
• Exhibits117: Alkem Laboratories Ltd. - Overview
• Exhibits118: Alkem Laboratories Ltd. - Business segments
• Exhibits119: Alkem Laboratories Ltd. - Key news
• Exhibits120: Alkem Laboratories Ltd. - Key offerings
• Exhibits121: Alkem Laboratories Ltd. - Segment focus
• Exhibits122: Apotex Inc. - Overview
• Exhibits123: Apotex Inc. - Product / Service
• Exhibits124: Apotex Inc. - Key offerings
• Exhibits125: AstraZeneca Plc - Overview
• Exhibits126: AstraZeneca Plc - Product / Service
• Exhibits127: AstraZeneca Plc - Key news
• Exhibits128: AstraZeneca Plc - Key offerings
• Exhibits129: Aurobindo Pharma Ltd. - Overview
• Exhibits130: Aurobindo Pharma Ltd. - Product / Service
• Exhibits131: Aurobindo Pharma Ltd. - Key offerings
• Exhibits132: Bayer AG - Overview
• Exhibits133: Bayer AG - Business segments
• Exhibits134: Bayer AG - Key news
• Exhibits135: Bayer AG - Key offerings
• Exhibits136: Bayer AG - Segment focus
• Exhibits137: Cipla Ltd. - Overview
• Exhibits138: Cipla Ltd. - Business segments
• Exhibits139: Cipla Ltd. - Key news
• Exhibits140: Cipla Ltd. - Key offerings
• Exhibits141: Cipla Ltd. - Segment focus
• Exhibits142: Dr Reddys Laboratories Ltd. - Overview
• Exhibits143: Dr Reddys Laboratories Ltd. - Business segments
• Exhibits144: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibits145: Dr Reddys Laboratories Ltd. - Segment focus
• Exhibits146: Eisai Co. Ltd. - Overview
• Exhibits147: Eisai Co. Ltd. - Business segments
• Exhibits148: Eisai Co. Ltd. - Key offerings
• Exhibits149: Eisai Co. Ltd. - Segment focus
• Exhibits150: Fresenius SE and Co. KGaA - Overview
• Exhibits151: Fresenius SE and Co. KGaA - Business segments
• Exhibits152: Fresenius SE and Co. KGaA - Key news
• Exhibits153: Fresenius SE and Co. KGaA - Key offerings
• Exhibits154: Fresenius SE and Co. KGaA - Segment focus
• Exhibits155: GlaxoSmithKline Plc - Overview
• Exhibits156: GlaxoSmithKline Plc - Business segments
• Exhibits157: GlaxoSmithKline Plc - Key offerings
• Exhibits158: GlaxoSmithKline Plc - Segment focus
• Exhibits159: iNova Pharmaceuticals - Overview
• Exhibits160: iNova Pharmaceuticals - Product / Service
• Exhibits161: iNova Pharmaceuticals - Key offerings
• Exhibits162: Johnson and Johnson - Overview
• Exhibits163: Johnson and Johnson - Business segments
• Exhibits164: Johnson and Johnson - Key news
• Exhibits165: Johnson and Johnson - Key offerings
• Exhibits166: Johnson and Johnson - Segment focus
• Exhibits167: Lupin Ltd. - Overview
• Exhibits168: Lupin Ltd. - Product / Service
• Exhibits169: Lupin Ltd. - Key news
• Exhibits170: Lupin Ltd. - Key offerings
• Exhibits171: Perrigo Co. Plc - Overview
• Exhibits172: Perrigo Co. Plc - Business segments
• Exhibits173: Perrigo Co. Plc - Key news
• Exhibits174: Perrigo Co. Plc - Key offerings
• Exhibits175: Perrigo Co. Plc - Segment focus
• Exhibits176: Inclusions checklist
• Exhibits177: Exclusions checklist
• Exhibits178: Currency conversion rates for US$
• Exhibits179: Research methodology
• Exhibits180: Validation techniques employed for market sizing
• Exhibits181: Information sources
• Exhibits182: List of abbreviations